Display Settings:

Format

Send to:

Choose Destination

    Biochem Biophys Res Commun. 2008 Jul 25;372(2):293-7. Epub 2008 May 22.

    H5N1 influenza marker vaccine for serological differentiation between vaccinated and infected chickens.

    Li C, Ping J, Jing B, Deng G, Jiang Y, Li Y, Tian G, Yu K, Bu Z, Chen H.

    Harbin Veterinary Research Institute, CAAS, 427 Maduan Street, Harbin, Heilongjiang 150001, People's Republic of China.

    Using plasmid-based reverse genetics, we generated a molecularly altered virus, H5N1/PR8-5B19, containing modified HA and NA genes from A/Goose/Guangdong/1/96 (GS/GD/1/96). In the H5N1/PR8-5B19 virus, the HA cleavage site was modified to resemble that of low-pathogenic avian strains and a portion of the NA stalk region was replaced by the immunodominant 5B19 epitope of the S2 glycoprotein of murine hepatitis virus (MHV). H5N1/PR8-5B19 is not lethal to embryonated eggs or chickens. Chickens immunized with the H5N1/PR8-5B19 inactivated vaccine produced high levels of HI antibody and a measurable antibody response against the MHV 5B19 epitope, and were fully protected against subsequent challenge with different highly pathogenic H5N1 avian influenza viruses. H5N1/PR8-5B19 is therefore an attractive marker vaccine candidate, eliciting a strong, protective antibody response and enabling serological discrimination between vaccinated and wild-type virus-infected chickens.

    PMID: 18501701 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read

    Patient drug information